Oak HC/FT is leading a $130 million Series B funding round for Chai Discovery, a company transforming drug development through advanced AI technologies.

Target Information

Chai Discovery is a pioneering company dedicated to revolutionizing the drug discovery and design landscape. With a mission to streamline the traditionally complex and lengthy drug development process, Chai aims to transform it into a more precise and programmable discipline. This is critical in an area where biopharmaceutical companies collectively spend over $290 billion annually on therapeutic development, yet have seen declining returns on investment due to escalating costs and stagnant technology adoption.

Since its inception, Chai has demonstrated remarkable progress, evolving from an open-source molecular structure prediction model (Chai-1) to a sophisticated de novo zero-shot antibody design engine (Chai-2) in just under a year. These groundbreaking innovations hold the potential to accelerate therapeutic development and explore previously difficult drug targets.

Industry Overview in the United States

The biopharmaceutical industry in the United States is undergoing significant changes, with increasing pressures to improve efficiency and reduce costs in therapy development. Over the past few decades, the return on investment for drug